A detailed history of Black Rock Inc. transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 16,445,682 shares of ALLO stock, worth $49.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,445,682
Previous 9,652,930 70.37%
Holding current value
$49.3 Million
Previous $43.1 Million 11.19%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.23 - $4.38 $15.1 Million - $29.8 Million
6,792,752 Added 70.37%
16,445,682 $38.3 Million
Q1 2024

May 10, 2024

SELL
$2.92 - $5.63 $1.02 Million - $1.96 Million
-348,874 Reduced 3.49%
9,652,930 $43.1 Million
Q4 2023

Feb 13, 2024

BUY
$2.28 - $3.5 $2.53 Million - $3.88 Million
1,107,824 Added 12.46%
10,001,804 $32.1 Million
Q3 2023

Nov 13, 2023

BUY
$3.17 - $5.96 $1.42 Million - $2.67 Million
447,930 Added 5.3%
8,893,980 $28.2 Million
Q2 2023

Aug 11, 2023

SELL
$4.53 - $6.74 $3.07 Million - $4.56 Million
-677,042 Reduced 7.42%
8,446,050 $42 Million
Q1 2023

May 12, 2023

BUY
$4.92 - $8.21 $1.16 Million - $1.94 Million
236,520 Added 2.66%
9,123,092 $45.1 Million
Q4 2022

Feb 13, 2023

BUY
$5.62 - $11.11 $3.79 Million - $7.49 Million
673,992 Added 8.21%
8,886,572 $55.9 Million
Q3 2022

Nov 14, 2022

BUY
$10.32 - $17.28 $2.14 Million - $3.58 Million
207,414 Added 2.59%
8,212,580 $88.7 Million
Q2 2022

Aug 12, 2022

BUY
$6.78 - $12.28 $6.23 Million - $11.3 Million
918,933 Added 12.97%
8,005,166 $91.3 Million
Q1 2022

May 12, 2022

BUY
$7.65 - $15.29 $4.29 Million - $8.57 Million
560,279 Added 8.59%
7,086,233 $64.6 Million
Q4 2021

Feb 10, 2022

SELL
$13.13 - $24.52 $9.78 Million - $18.3 Million
-745,238 Reduced 10.25%
6,525,954 $97.4 Million
Q3 2021

Nov 09, 2021

BUY
$21.01 - $27.64 $5.24 Million - $6.89 Million
249,253 Added 3.55%
7,271,192 $187 Million
Q2 2021

Aug 11, 2021

BUY
$23.49 - $35.8 $165 Million - $251 Million
7,021,939 New
7,021,939 $183 Million

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $431M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.